4//SEC Filing
Sullivan Lara 4
Accession 0001209191-23-021415
CIK 0001782223other
Filed
Mar 27, 8:00 PM ET
Accepted
Mar 28, 4:48 PM ET
Size
14.9 KB
Accession
0001209191-23-021415
Insider Transaction Report
Form 4
Sullivan Lara
DirectorPresident ,CEO & CMO
Transactions
- Award
Common Stock
2023-03-24+703,379→ 2,155,699 total - Disposition to Issuer
Stock Option (Right to buy)
2023-03-24−990,461→ 0 totalExercise: $5.34Exp: 2031-03-30→ Common Stock (990,461 underlying) - Award
Stock Option (Right to buy)
2023-03-24+990,461→ 990,461 totalExercise: $2.21Exp: 2031-03-30→ Common Stock (990,461 underlying) - Award
Stock Option (Right to buy)
2023-03-24+61,825→ 61,825 totalExercise: $2.21Exp: 2031-09-14→ Common Stock (61,825 underlying) - Disposition to Issuer
Stock Option (Right to buy)
2023-03-24−61,825→ 0 totalExercise: $8.71Exp: 2031-09-14→ Common Stock (61,825 underlying)
Footnotes (4)
- [F1]Represents restricted stock units that vest 25% on March 24, 2024, and then in 36 substantially-equal monthly installments thereafter, subject to the reporting person's continued employment through the applicable vesting date.
- [F2]In accordance with the terms of the Pyxis Oncology, Inc. 2019 Equity and Incentive Plan (the "Plan"), the Board of Directors of Pyxis Oncology, Inc. approved a stock option repricing pursuant to which option awards granted under the Plan were amended to reduce the exercise price to $2.21 per share, the closing stock price on the date of Board approval. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements.
- [F3]These stock options vest in 48 substantially-equal monthly installments beginning January 2, 2020, subject to the reporting person's continued employment through the applicable vesting date.
- [F4]These stock options vested 25% on the first anniversary of the closing of the Issuer's initial public offering, and then vests in 36 substantially-equal monthly installments thereafter, subject to the reporting person's continued employment through the applicable vesting date.
Documents
Issuer
Pyxis Oncology, Inc.
CIK 0001782223
Entity typeother
Related Parties
1- filerCIK 0001769457
Filing Metadata
- Form type
- 4
- Filed
- Mar 27, 8:00 PM ET
- Accepted
- Mar 28, 4:48 PM ET
- Size
- 14.9 KB